ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Subscribe To Our Newsletter & Stay Updated